Sign in

You're signed outSign in or to get full access.

Radhika Mereddy

Director at Syra Health
Board

About Radhika Mereddy

Radhika Mereddy, 49, joined Syra Health’s Board in August 2025 and is a Senior Systems Manager at the Pension Fund of the Christian Church, where she has held roles of increasing responsibility since 2013 . She holds a Master’s degree in Management Information Systems from Ferris State University and a Bachelor’s in engineering from PDA Engineering College, with a profile emphasizing information systems and business process improvement .

Past Roles

OrganizationRoleTenureCommittees/Impact
Pension Fund of the Christian ChurchSenior Systems ManagerSince 2013Information systems and process improvement; technology leverage for reliability and speed

External Roles

OrganizationRoleTenureNotes
Not disclosedNo other public company directorships or committee roles disclosed in SYRA proxy biography

Board Governance

  • Board independence review in 2025 named three independent directors (Vijayapal Reddy, Ketan Paranjape, Avutu Reddy); Mereddy was not listed in that independent cohort, and her independence status was not explicitly disclosed .
  • As of December 31, 2024, committee membership was: Audit (Rogers—Chair; Paranjape; Avutu Reddy), Compensation (Avutu Reddy—Chair; Vijayapal Reddy), Nominating & Governance (Vijayapal Reddy—Chair; Avutu Reddy); Mereddy joined in August 2025 and no committee assignment was disclosed for her in the 2025 proxy .
  • Board leadership structure: no Chairman of the Board disclosed for 2025 .
  • Attendance context: In 2024, the Board held 8 meetings; none of the directors attended fewer than 75% of combined Board/committee meetings during their tenure; Mereddy was not a director in 2024, and no attendance data was disclosed for her .

Fixed Compensation

Non-employee director cash compensation policy approved March 26, 2025 (applicable during Mereddy’s tenure):

ComponentAmount (USD)Notes
Annual cash retainer (non-employee directors)$20,000Paid in quarterly installments
Audit Committee Chair$10,000Additional annual cash compensation
Compensation Committee Chair$5,000Additional annual cash compensation
Nominating & Governance Committee Chair$5,000Additional annual cash compensation
Committee membership fee (each committee)$2,000Additional annual cash compensation
  • Actual amounts earned by Mereddy in 2025 were not itemized in the proxy; policy terms above apply to non-employee directors .

Performance Compensation

  • No performance-based metrics were disclosed for director compensation; 2025 policy describes cash retainers and chair/member fees without equity or metric-linked pay .

Context: 2024 option grants to then-serving directors (Mereddy was not yet on the Board)

DirectorGrant DateOptions (#)Exercise PriceTermVesting
Andrew DahlemNov 14, 202411,581$0.368310 years25% at grant; remainder in 12 equal monthly installments
Ketan ParanjapeNov 14, 202419,303$0.368310 yearsAs above
Avutu ReddyNov 14, 202415,442$0.368310 yearsAs above
Vijayapal ReddyNov 14, 202415,442$0.368310 yearsAs above
Sherron RogersNov 14, 202411,581$0.368310 yearsAs above

Other Directorships & Interlocks

  • No other public company board service or disclosed interlocks for Mereddy in SYRA’s 2025 proxy .

Expertise & Qualifications

  • Education: Master’s in MIS (Ferris State University); Bachelor’s in engineering (PDA Engineering College) .
  • Functional expertise: information systems and business process improvement; leveraging technology and information to drive reliability and speed .

Equity Ownership

  • Beneficial ownership (as of September 17, 2025): Mereddy reported no Class A or Class B holdings in the beneficial ownership table .
  • Ownership alignment context: Directors are subject to an anti-hedging policy; pledging requires specific exception by the chief compliance officer, mitigating misalignment risks from hedging/pledging practices .
HolderClass A SharesClass B SharesVoting Power (%)
Radhika Mereddy00Not listed (table shows “—” for her)

Insider Trades

Date RangeFiling(s)Notes
FY2024Section 16(a) delinquency disclosuresOnly Priya Prasad was noted for one late Form 4; Mereddy was not listed among delinquent filers

Governance Assessment

  • Independence and committee role clarity: Mereddy is a new director (Aug 2025) and was not named in the independence cohort disclosed (three of five directors); lack of explicit independence confirmation and unspecified committee assignments reduce transparency on her oversight role and board effectiveness for 2025 .
  • Ownership alignment: As of Sept 17, 2025, Mereddy reported no beneficial ownership, which, combined with 2025 cash-only director compensation structure, suggests limited direct alignment via equity unless grants occur later .
  • Anti-hedging policy: The company’s policy prohibits hedging and derivative transactions and restricts pledging, supporting alignment and investor confidence; exceptions to pledging require demonstrable repayment capacity without resort to pledged securities .
  • Dual-class governance changes (RED FLAG for entrenchment risk): 2025 proposals remove automatic conversion of Class B upon a holder’s death and permit transfers of Class B to family, heirs, successors, and assigns without conversion—potentially preserving super-voting control across generations and affecting voting dynamics and long-term shareholder composition .
  • Related-party environment: The company disclosed related-party transactions with entities associated with certain executives and affiliates (e.g., STVentures lease; RAD CUBE; NLogix; STLogics advances) but none specifically involving Mereddy; these arrangements warrant continued audit committee scrutiny to avoid conflicts .
  • Attendance culture: Board met 8 times in 2024 and directors met attendance thresholds; no data disclosed yet for Mereddy given her 2025 appointment .

Overall signal: Mereddy brings systems and process expertise relevant to technology-enabled healthcare operations, but current disclosures provide limited clarity on her independence, committee roles, and equity alignment; coupled with dual-class amendments that may entrench control, investors should monitor her future committee assignments, any equity grants, and Section 16 filings to assess governance alignment and engagement .